PRDS News and Press, Pardes Biosciences Inc. From 03/03/22

CARLSBAD, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections ...

Pardes Biosciences (NASDAQ:PRDS) appointed Thomas Wiggans as CEO and chair of the board. Uri Lopatin will remain on the board and continue to play an active role in PRDS' R&D activities as chief scientific & strategic advisor. Mark Auerbach will transition from chairman to director. W...

Mr. Wiggans brings over 40 years of biopharmaceutical industry experience, including over 25 years in chief executive leadership roles with multiple successful acquisitions. His expertise will be beneficial to Pardes as the company rapidly progresses to late-stage development and regulato...

The following slide deck was published by Pardes Biosciences, Inc. in conjunction with this event. For further details see: Pardes Biosciences (PRDS) presents at CROI 2022 - Slideshow

The following slide deck was published by Pardes Biosciences, Inc. in conjunction with this event. For further details see: Pardes Biosciences (PRDS) Investor Presentation - Slideshow

PBI-0451 administered twice-daily as a stand-alone agent achieves and maintains PK exposures anticipated to provide potent antiviral activity against SARS-CoV-2 PBI-0451 has been generally well-tolerated and has shown good oral bioavailability Company to host conference ...

CARLSBAD, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associa...

CARLSBAD, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associa...

The U.S Food and Drug Administration (FDA) cleared Pardes Biosciences' (NASDAQ:PRDS) investigational new drug (IND) application for its oral antiviral PBI-0451 to enter trials for treating and preventing of SARS-CoV-2 infections. “The clearance of our IND for PBI-0451 enables us t...

CARLSBAD, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associa...